Published: 2018-02-23

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis

Kristian Reich, Mark Lebwohl, Carle Paul, Mads Ropke, Monika Rosen, Klaus Hansen
| DOI https://doi.org/10.25251/skin.2.supp.1

Page S1

Poster PDF

Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study

Carle Paul, Craig Leonardi, Alan Menter, Kristian Reich, Linda Stein Gold, Richard B Warren, Anders Moller, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.2.supp.2

Page S2

Poster PDF

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials

Andrew Blauvelt, Kristian Reich, Mark Lebwohl, Daniel Burge, Catherine Arendt, Luke Peterson, Robert Rolleri, Alice Gottlieb
| DOI https://doi.org/10.25251/skin.2.supp.3

Page S3

Poster PDF

Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies

Kim Papp, Kristian Reich, Andrew Blauvelt, Diamant Thaci, Rodney Sinclair, Stephen K Tyring, Nicole Cichanowitz, Stuart Green, Qing Li, Carmen La Rosa
| DOI https://doi.org/10.25251/skin.2.supp.4

Page S4

Poster PDF

Combination of Calcipotriene Foam, 0.005% and Tazarotene Foam, 0.1% in the Treatment of Plaque Psoriasis of the Scalp and Body: A Case Report

Hee J Kim, Mark G Lebwohl
| DOI https://doi.org/10.25251/skin.2.supp.5

Page S5

Poster PDF

Distribution of Depression and Suicidality in a Psoriasis Clinical Trial Population

Steven R Feldman, Susan Harris, Shipra Rastogi, Robert J Israel
| DOI https://doi.org/10.25251/skin.2.supp.6

Page S6

Poster PDF

Efficacy and Safety of Brodalumab in Obese Patients with Moderate-to-Severe Plaque Psoriasis

Abby S Van Voorhees, Sylvia Hsu, Boni Elewski, Shipra Rastogi, Robert J Israel
| DOI https://doi.org/10.25251/skin.2.supp.7

Page S7

Poster PDF

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis

Caitriona Ryan, Alan Menter, Lyn Guenther, Andrew Blauvelt, Robert Bissonnette, Fan E Yang, Allison P Bleakman, David A Amato
| DOI https://doi.org/10.25251/skin.2.supp.8

Page S8

Poster PDF

Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial

Alan Menter, Jeff Sobell, Jonathan I Silverberg, Mark Lebwohl, Shipra Rastogi, Radhakrishnan Pillai, Robert J Israel
| DOI https://doi.org/10.25251/skin.2.supp.9

Page S9

Poster PDF

Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Jennifer Soung, Lisa Tiu, Karen Veverka, Chih-Ho Hong
| DOI https://doi.org/10.25251/skin.2.supp.10

Page S10

Poster PDF

Patient Preferences for Vehicle and Overall Preference of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam and Gel in the PSO-INSIGHTFUL Study

Chih-Ho Hong, Dharm S Patel, Katja W Lophaven
| DOI https://doi.org/10.25251/skin.2.supp.11

Page S11

Poster PDF

Psoriasis Patients on Chronic Biologic Therapy May Benefit from Additional Treatment-Study Design and Baseline Characteristics

Jerry Bagel, James Zapata, Elise Nelson, Brian Keegan
| DOI https://doi.org/10.25251/skin.2.supp.13

Page S12

Poster PDF

The Psoriasis Patient Journey: Progression from Topical to Biologic Treatment for Psoriasis Patients in the United States

Jashin J Wu, Minyi Lu, Karen A Veverka, Maartje Smulders, Eros Papademetriou, Yunjua Junhua, Steven R Feldman
| DOI https://doi.org/10.25251/skin.2.supp.12

Page S13

Poster PDF

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Desiree van der Heijde, Masato Okada, Chin Lee, Catherine L Shuler, Suchitrita Rathmann, Chen-Yen Lin, David Amato, Philip J Mease
| DOI https://doi.org/10.25251/skin.2.supp.14

Page S14

Poster PDF

Real World Experience with Calicpotriene and Betamethasone Dipropionate Foam 0.005%/0.064% (Cal/BD Foam) in the Treatment of Adult Psoriasis Itch from Retrospective Chart Review

Jashin Wu, Karen Veverka, Minyi Lu, April W Armstrong
| DOI https://doi.org/10.25251/skin.2.supp.15

Page S15

Poster PDF

Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies

A Blauvelt, B Strober, R Langley, D Burge, L Pisenti, M Yassine, S Kavanagh, C Arendt, R Rolleri, K Reich
| DOI https://doi.org/10.25251/skin.2.supp.16

Page S16

Poster PDF

Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 2-Year Results from a Phase 3 Study

LC Coates, DD Gladman, P Nash, O FitzGerald, A Kavanaugh, L Rasouliyan, L Pricop, K Ding, C Gaillez
| DOI https://doi.org/10.25251/skin.2.supp.17

Page S17

Poster PDF

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

PCM van de Kerkhof, K Reich, CL Leonardi, A Blauvelt, NN Mehta, TF Tsai, R You, P Papanastasiou, M Milutinovic, CEM Griffiths
| DOI https://doi.org/10.25251/skin.2.supp.18

Page S18

Poster PDF

Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials

A Blauvelt, A Armstrong, P Rich, R Kisa, A Guana, X Meng, K Callis Duffin
| DOI https://doi.org/10.25251/skin.2.supp.19

Page S19

Poster PDF

Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study

E von Stebut, K Reich, D Thaci, W Koenig, A Pinter, A Korber, T Rassaf, A Waisman, V Mani, D Yates, J Frueh, C Sieder, N Melzer, T Gori
| DOI https://doi.org/10.25251/skin.2.supp.20

Page S20

Poster PDF

Secukinumab Sustains Individual Clinical Responses Over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial

P Emery, IB McInnes, PJ Mease, M Schiff, L Pricop, S Shen, Z Wang, C Gaillez
| DOI https://doi.org/10.25251/skin.2.supp.21

Page S21

Poster PDF

Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis

Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan Mendelsohn, Jeffrey Parno, Kenneth Gordon
| DOI https://doi.org/10.25251/skin.2.supp.22

Page S22

Poster PDF

Sustained Improvement in Patient-Reported Outcomes with Continued Apremilast Treatment over 104 Weeks in Patients with Moderate to Severe Psoriasis

M Shane Chapman, Joshua Cirulli, Sandy McBride
| DOI https://doi.org/10.25251/skin.2.supp.23

Page S23

Poster PDF

Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis

Linda Stein Gold, Paul Yamauchi, David Pariser, Zhenyi Xu, Marie L Osterdal, Jerry Bagel
| DOI https://doi.org/10.25251/skin.2.supp.24

Page S24

Poster PDF

US Patient Satisfaction with Secukinumab Treatment Among Patients with Both Psoriatic Arthritis and Psoriasis: Data from a Web-Based Survey

Marina Magrey, Daniel Wolin, Margaret Mordin, Lori McLeod, Eric Davenport, Peter Hur
| DOI https://doi.org/10.25251/skin.2.supp.25

Page S25

Poster PDF

Vasoconstrictor Potencey of Fixed Combination Calcipotriol Plus Betamethasone Dipropionate Foam Versus Other Corticosteroid Psoriasis Treatments

Catherine Queille-Roussel, Jakob Nielsen
| DOI https://doi.org/10.25251/skin.2.supp.26

Page S26

Poster PDF

Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis: CLARITY, a Randomized, Controlled, Phase 3b Trial

Jerry Bagel, John Nia, Peter Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Elsa Muscianisi, Andrew Blauvelt, Mark Lebwohl

Page S27

Poster PDF

Atopic Dermatitis

A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis

TM Weber, CE Arrowitz, U Scherdin, AM Schoelermann, A Filbry
| DOI https://doi.org/10.25251/skin.2.supp.27

Page S28

Poster PDF

A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Andreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, Jonathan I Silverberg, Claire Birrell, Christopher Kell, Koustubh Ranade, Michelle Dawson, Rene van der Merwe
| DOI https://doi.org/10.25251/skin.2.supp.28

Page S29

Poster PDF

A Real-World Study Evaluating AdeQUacy of Existing Systematic Treatments for Patients with Moderate-to-Severe Atopic Dermatitis (AD-QUEST): Baseline Treatment Patterns and Unmet Needs Assessment

Wenhui Wei, Eric Ghorayeb, Michael Andria, Valery Walker, Jingdong Chao, James Schnitzer, Martha Kennedy, Zhen Chen, Angela Belland, John White, Jonathan I Silverberg
| DOI https://doi.org/10.25251/skin.2.supp.29

Page S30

Poster PDF

Hyperhidrosis

Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness

David M Pariser, Adelaide A Hebert, Janice Drew, John Quiring, Dee Anna Glaser
| DOI https://doi.org/10.25251/skin.2.supp.39

Page S39

Poster PDF

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis

Dee Anna Glaser, Adelaide A Hebert, Alexander Nast, William P Werschler, Stephen Shideler, Lawrence Green, Richard D Mamelok, Janice Drew, John Quiring, David M Pariser
| DOI https://doi.org/10.25251/skin.2.supp.40

Page S40

Poster PDF

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

David M Pariser, Adelaide A Hebert, Janice Drew, John Quiring, Dee Anna Glaser
| DOI https://doi.org/10.25251/skin.2.supp.41

Page S41

Poster PDF

Rosacea

Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study

N Bhatia, M Ahmadyar, H Hansra, J Del Rosso, H Baldwin, AM Daniels
| DOI https://doi.org/10.25251/skin.2.supp.34

Page S35

Poster PDF

Patient Concerns and Treatment Satisfaction in Patients Treated with Azelaic Acid Foam for Rosacea

T Williamson, J Cameron, K McLeod, B Turner, A Quillen, A LaRose
| DOI https://doi.org/10.25251/skin.2.supp.35

Page S36

Poster PDF

Cosmetic

Efficacy of an Ointment Body Spray to Improve the Appearance of Dry, Ashy Skin and Alleviate Moderate to Severe Dryness on the Heel

TM Weber, CE Arrowitz, LI Jiang, K Qian, A Filbry
| DOI https://doi.org/10.25251/skin.2.supp.37

Page S37

Poster PDF

Protective Effect of a Novel Anti-Aging Facial Cream Containing Alteromonas Ferment Extract and Carnosine Against Environmental Pollution in Human Skin Explants in Ex-Vivo Study

M Narda, C Granger
| DOI https://doi.org/10.25251/skin.2.supp.38

Page S38

Poster PDF

Melanoma

Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort

Martin Fleming, Clare Johnson, Kyle Covington, Joseph Gadzia, Larry Dillon, Federico A Monzon
| DOI https://doi.org/10.25251/skin.2.supp.42

Page S42

Poster PDF

Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma

Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandala, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Drummer, John M Kirkwood
| DOI https://doi.org/10.25251/skin.2.supp.43

Page S43

Poster PDF

A Retrospective Case Series to Evaluate the Clinical Utility of a 31-Gene Expression Profile Test in Cutaneous Melanoma Patients

Robert W Cook, Federico A Monzon, David Hyams
| DOI https://doi.org/10.25251/skin.2.supp.44

Page S44

Poster PDF

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study

Kyriakos P Papadopoulos, Taofeek K Owonikoko, Melissa L Johnson, Irene Brana, Marta Gil-Martin, Raymond P Perez, Victor Moreno, April K Salama, Emiliano Calvo, Nelson S Yee, Howard Safran, Antonio Gonzalez-Martin, Raid Aljumaily, Daruka Mahadevan, Kosalai K Mohan, Jingjin Li, Elizabeth Stankevich, Israel Lowy, Matthew G Fury, Jade Homsi
| DOI https://doi.org/10.25251/skin.2.supp.45

Page S45

Poster PDF

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial

C William Hanke, Lorne Albrecht, Laerke K Kyhl, Thomas Larrson, Marie L Oesterdal, Lynda Spelman
| DOI https://doi.org/10.25251/skin.2.supp.46

Page S46

Poster PDF

Long-Term Safety of Sonidegib in Basal Cell Carcinoma: 30-Month Results from the BOLT Trial

Ragini Kudchadkar, Anne Lynn S Chang
| DOI https://doi.org/10.25251/skin.2.supp.47

Page S47

Poster PDF

Real-World Treatment and Patient-Specific Characteristics of Actinic Keratosis in the USA

Jes B Hansen, Mads D Faurby, Meg Corliss, Steven R Feldman
| DOI https://doi.org/10.25251/skin.2.supp.48

Page S48

Poster PDF

Safety and Efficacy of A-101 Hydrogen Peroxide Topical Solution 40% in Adults with Seborrheic Keratosis: Results from the Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study

Zoe D Draelos, Steven E Kempers, Stacy R Smith, David C Wilson, Christopher V Powala, Mark Bradshaw, Esther Estes, Stuart D Shanler
| DOI https://doi.org/10.25251/skin.2.supp.49

Page S49

Poster PDF

Sonidegib Duration of Response in Advanced Basal Cell Carcinoma: Long-term Results from the Phase 2 BOLT Trial

Anne Lynn S Chang, Ragini Kudchadkar
| DOI https://doi.org/10.25251/skin.2.supp.50

Page S50

Poster PDF

Urticaria

Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Lang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakaosy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.2.supp.51

Page S51

Poster PDF

Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study

Wayne Gulliver, Gordon Sussman, Jacques Hebert, Charles W Lynde, Kim A Papp, William H Yang, Olivier Chambenoit, Antonio Viera, Frederica DeTakaosy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.2.supp.52

Page S52

Poster PDF

Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study

Karsten Weller, Petra Staubach, Martin Metz, Nadine Chapman-Rothe, Christian Sieder, Matthias Brautigam, Marcus Maurer
| DOI https://doi.org/10.25251/skin.2.supp.53

Page S53

Poster PDF

Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica DeTakaosy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.2.supp.54

Page S54

Poster PDF

Miscellaneous

Use of an Investigator's Global Assessment Scale to Evaluate Disease Severity in Patients swith Epidermolysis Bullosa Simplex

Johann W Bauer, Amy Paller, Jemima E Mellerio, Alain Hovnanian, John J Pan, Panagiotis Zografaos, Greg P Licholai, Dedee F Murrell
| DOI https://doi.org/10.25251/skin.2.supp.55

Page S55

Poster PDF

Acne & Rosacea

The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies

Linda Stein Gold, Sunil Dhawan, Jonathan Weiss, Zoe D Draelos, Herman Ellman
| DOI https://doi.org/10.25251/skin.2.supp.30

Page S31

Poster PDF

Efficacy, Tolerability, and Safety of SB204 Gel in Adolescents (9 to 17 Years of Age) with Acne Vulgaris

Diane Thiboutot, Andrea Zaenglein, Adelaide Hebert, Lawrence Eichenfield
| DOI https://doi.org/10.25251/skin.2.supp.31

Page S32

Poster PDF

An Open-Label Study Evaluating the Long-Term Efficacy, Quality of Life, and Safety of Lidose-Isotretinoin (ABSORICA) Capsules Administered Without Food in Patients with Severe Recalcitrant Nodular Acne: Interim Analysis of 20-Week Active Treatment Period

Andrea Zaenglein, James Del Rosso
| DOI https://doi.org/10.25251/skin.2.supp.32

Page S33

Poster PDF

Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies

Terry M Jones, Herman Ellman, Tina deVries
| DOI https://doi.org/10.25251/skin.2.supp.33

Page S34

Poster PDF